Source comparison
Comparison: TB-500 Protocol Variations by Age Group
20–29 2.0mg 2×/week 3–4 weeks 2.0mg 1×/week 2–4 weeks High endogenous thymosin beta-4; rapid receptor response Standard protocols work well; shorter maintenance sufficient 30–39 2.0–2.5mg 2×/week 4–6 weeks 4–8 weeks Declining receptor density; slower cytokine
This comparison does not assign a generated winner or score.
- 20–29
- 2.0mg 2×/week
- 3–4 weeks
- 2.0mg 1×/week
- 2–4 weeks
- High endogenous thymosin beta-4; rapid receptor response
- Standard protocols work well; shorter maintenance sufficient
- 30–39
- 2.0–2.5mg 2×/week
- 4–6 weeks
- 4–8 weeks
- Declining receptor density; slower cytokine clearance
- Extended loading + maintenance required for full tissue remodeling
- 40–49
- 2.5mg 2×/week
- 6–8 weeks
- 2.0–2.5mg 1×/week
- 6–10 weeks
- Significantly reduced satellite cell activation; longer inflammation tail
- Highest dose + longest duration needed; adjunct therapies (collagen, vitamin C) improve outcomes